Travere Therapeutics, Inc.
TVTX
$17.92
$0.130.73%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -15.86% | -40.70% | -188.64% | -303.74% | 38.64% |
| Total Depreciation and Amortization | 21.75% | 11.22% | 13.04% | 15.83% | 72.49% |
| Total Amortization of Deferred Charges | 0.41% | 0.41% | 0.41% | 5.92% | 5.92% |
| Total Other Non-Cash Items | 124.45% | 152.66% | 155.51% | 156.35% | -417.33% |
| Change in Net Operating Assets | 53.37% | -1,040.93% | -147.38% | -71.79% | -92.33% |
| Cash from Operations | 60.04% | 49.46% | 15.19% | -3.04% | -18.10% |
| Capital Expenditure | -127.77% | -100.00% | -- | 183.36% | 183.11% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -95.14% | -81.88% | 78.08% | 341.78% | 358.02% |
| Cash from Investing | -95.21% | -81.93% | 78.08% | 351.59% | 386.51% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 6,090.11% | 3,447.46% | -28.38% | -98.60% | -98.81% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 19.82% | 27.03% | -109.93% | -111.34% | -112.13% |
| Cash from Financing | 57,158.50% | 11,570.59% | -36.26% | -99.81% | -100.11% |
| Foreign Exchange rate Adjustments | 206.01% | -108.57% | -146.09% | -32.21% | -68.66% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 211.09% | 115.78% | 110.22% | -1,420.30% | 64.57% |